Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS5545628 A
Publication typeGrant
Application numberUS 08/370,883
Publication dateAug 13, 1996
Filing dateJan 10, 1995
Priority dateJan 10, 1995
Fee statusPaid
Also published asCA2210985A1, CA2210985C, DE69627817D1, EP0801562A1, EP0801562B1, EP0801562B2, WO1996021439A1
Publication number08370883, 370883, US 5545628 A, US 5545628A, US-A-5545628, US5545628 A, US5545628A
InventorsArthur Deboeck, Paul Maes, Phillipe R. Baudier
Original AssigneeGalephar P.R. Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Pharmaceutical composition containing fenofibrate
US 5545628 A
Abstract
A pharmaceutical composition is provided for treating hyperlipidemia or hypercholesterolemia or both in a mammal, which contains an effective amount of each of fenofibrate and an excipient containing one or more polyglycolyzed glycerides.
Images(6)
Previous page
Next page
Claims(15)
What is claimed as new and desired to be secured by Letters Patent of the United States is:
1. A pharmaceutical composition for treating hyperlipidemia or hypercholesterolemia or both in a mammal, which comprises an effective amount of each of fenofibrate and an excipient comprising one or more polyglycolyzed glycerides.
2. The composition of claim 1, wherein said fenofibrate is present in an amount of 5% to 95% by weight based on the total weight of the composition.
3. The composition of claim 1, wherein the polyglycolyzed glycerides have a HLB value of at least 10.
4. The composition of claim 3, wherein the polylglycolyzed glycerides have a HLB value of from 12 to 15.
5. The composition of claim 1, which further comprises polyalkylene glycols to adjust the HLB value or melting point or both to the desired value.
6. The composition of claim 1, wherein a suspension stabilizer is added.
7. The composition of claim 6, wherein said suspension stabilizer is selected from the group and consisting of cellulose, povidone, poloxamers, α, Ω-hydroxy-poly(oxyethylene) poly(oxypropylene)-poly(oxyethylene)bloc polymers.
8. The composition of claim 1, in which said fenofibrate and said excipient are in unit dosage form and are contained in a hard gelatin capsule.
9. The composition of claim 8, wherein said hard gelatin capsule contains from about 67 mg to about 200 mg of fenofibrate.
10. A method of making a solid oral dosage form of a pharmaceutical composition, comprising an effective amount of each of fenofibrate and an excipient comprising one or more polyglycolyzed glycerides, which method comprises adding said molten fenofibrate and said excipient to hard gelatin capsules, and allowing said said molten fenofibrate and said excipient to cool therein.
11. A method of treating hyperlipidemia or hypercholesterolemia or both in a mammal in need threof, which comprises administering to said mammal an effective amount of a pharmaceutical composition, comprising fenofibrate and an excipient containing one or more polyglycolyzed glycerides.
12. The method of claim 11, wherein said mammal is human, and said effective amount of fenofibrate in said composition is from about 100 mg to 600 mg per day.
13. The method of claim 12, wherein said effective amount of fenofibrate in said composition is from about 100 mg to 300 mg per day.
14. The method of claim 11, wherein said composition is administered orally.
15. The method of claim 10, which is with the proviso that the fenofibrate used is not co-micronized.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to a pharmaceutical dosage form of fenofibrate having enhanced bioavailability, as well as to an advantageous process for making the same.

2. Description of the Background

Fenofibrate or P-(4-chlorobenzoyl)-phenoxy isobutyrate isopropyl ester is useful for the treatment of adult patients with very high elevations of serum triglyceride levels and/or cholesterol levels. The usual daily dosage is 300 mg which is administered in two or three doses. Fenofibrate is absorbed as fenofibric acid which is responsible for the pharmacological activity. Fenofibric acid resulting from the hydrolysis of fenofibrate is extensively bound to plasma albumin. The plasma half-life is about 20 hours. Fenofibric acid is excreted predominantly in the urine, mainly as the glucuronide conjugate, but also as a reduced form of fenofibric acid and its glucuronides.

Fenofibrate, is presently available in a pharmaceutical dosage form consisting of hard gelatin capsules containing fenofibrate, lactose starch and magnesium stearate. After oral administration, during a meal, about 60% of the dose of this conventional form is effectively absorbed and found in the blood as fenofibric acid, the main metabolite responsible for pharmacological activity. (Strolin & A1, Act Pharmacal. Toxicol. 1986; 59 (Suppl. 5); 167).

The first attempt to improve the bioavailability of fenofibrate was performed by Ben-Armor and A1, by solubilizing the fenofibrate in dimethyl isosorbide, a nonaqueous solvent with a miscible wetting agent (Labrafil M1944CS) with HLB of between 3-4. In order to use the product in capsules, colloidal silicon oxide was added to increase the viscosity. The liquid so obtained was placed in hard gelatin capsules which, to be leak proof, were sealed. In vivo studies with this formulation indicate that there was no statistically significant difference in bioavailability between this liquid formulation and the conventional form when the product was given with food.

European Patent Application 0330532 discloses a fenofibrate composition wherein the fenofibrate powder is co-micronized with a solid wetting agent. Sodium lauryl sulfate is described as the solid wetting agent of choice. The co-micronized powder so obtained is mixed with capsule filling excipient such as lactose, starch, polyvinyl pyrollidone and magnesium stearate. A formulation of this composition is actually available on the French market under the trade name Lypantyl 200 M®. A study comparing this formulation (Lypantyl 200 M®) to the conventional form was undertaken and a statistically significant increase in bioavailability was indicated for the former. In particular, it was found that 67 mg of the new form gives the same amount absorbed as does 100 mg of the conventional form. (J. L. Suichard & Al Cun Therapeutic Research Vol. 54, NS, Nov. 1993).

Unfortunately, co-micronization of the active drug fenofibrate with the wetting agent sodium lauryl sulfate, although necessary, is a time consuming and costly operation. Further, an inherent drawback of micronization is that the material obtained must comply with very stringent particle size specifications.

Moreover, the filling of hard gelatin capsules with a micronized powder is a difficult operation, particularly if weight variation homogeneity is considered.

Hence, a need exists for a fenofibrate formulation that avoids the use of co-micronization, while providing a bioavailability comparable to that afforded by the conventional fenofibrate formulation which uses co-micronization.

SUMMARY OF THE INVENTION

Accordingly, it is an object of the present invention to provide a fenofibrate formulation not requiring use of co-micronization which, nevertheless, exhibits a bioavailability comparable to formulations of fenofibrate which do.

It is also an object of the present invention to provide a solid, oral dosage form of a fenofibrate formulation that can be prepared by melting the excipients in which the fenofibrate is soluble and, therefore, does not require any particle size specification.

The above objects and others are provided by a pharmaceutical composition for treating hyperlipidemia in and/or hypercholeslerolemia a mammal, which contains an effective amount of each of fenofibrate and an excipient containing one or more polyglycolized glycerides.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention provides a pharmaceutical formulation for treating hyperlipidemia and/or hypercholesterolemia in a mammal, which contains an effective amount of each of a fenofibrate composition and an excipient which contains one or more polyglycolyzed glycerides, the polyglycolyzed glycerides preferably having an HLB value of at least about 10.

The prevent invention is also particularly advantageous for the production of oral solid dosage forms which can be prepared by melting the excipients in which the fenofibrate is soluble, whereby particle size specifications are not required.

The present invention also relates to the addition of a suspension stabilizer to the molten solution of fenofibrate-polyglycolyzed glycerides. The suspension stabilizer avoids the formation of fenofibrate crystals during the cooling of the filled hard gelatin capsules. Suitable suspension stabilizers which may be used are, for example, cellulose derivatives, such as hydroxypropylcellulose, hydroxypropylmethyl cellulose, methyl cellulose, and hydroxyethylcellulose, povidone, poloxamers, α, Ω-hydroxy-poly(oxyethylene) poly(oxypropylene)-poly(oxyethylene)bloc polymers. Other suspension stabilizers equivalent to these stabiliers may, of course, also be used.

The present invention is also particularly advantageous for the production of a pharmaceutical composition in that the hot, homogeneous fenofibrate solution is filled in hard gelatin capsules. This filling process permits the obtention of very precise fenofibrate amounts in each capsule.

The present invention is particularly advantageous as well for the production of the present pharmaceutical composition in that the process for manufacturing the composition requires very few steps such as melting, mixing and filling. This renders the present manufacturing process extremely cost effective when compared to one using co-micronization of powders.

Polyglycolyzed glycerides which may be used in the present invention are generally mixtures of known monoesters, diesters and triesters of glycerols and known monoesters and diesters of polyethylene glycols with a mean relative molecular mass between about 200 and 6000. They may be obtained by partial transesterification of triglycerides with polyethylene glycol or by esterification of glycerol and polyethylene glycol with fatty acids using known reactions. Preferably, the fatty acid component contains 8-22 carbon atoms, particularly 10-18 carbon atoms. Examples of natural vegetable oils which may be used include palm kernel oil and palm oil. However, these are only examples. The polyol suitably has a molecular weight in the range of about 200-6000 and preferably contains polyethylene glycol, although other polyols may be employed, such as polyglycerols or sorbitol. They are available on the market under the trade name Gelucire®.

As noted above, the HLB of the polyglycolized glycerides is preferably at least about 10, and more preferably between about 12 and 15. The melting point of the polyglycolized glycerides may be between about 18° C. and 60° C. However, it is especially desirable to use polyglycolized glycerides having a melting point above 30° C., and preferably above 35° C., since there is no need for sealing the capsule, to assure the leak proofness thereof, when such excipients are used.

Further, two or more polyglycolized glycerides may be mixed in order to adjust both the HLB value and the melting point to a desired value. The HLB value and melting point of the composition may further be adjusted with the addition of components such as polyethylene glycols, polyoxyethylene glycols fatty acid esters, and fatty acid alcohols. In view of the present specification, it is well within the skill of the artisan to mix the polyglycolized glycerides to obtain desired HLB values and melting points.

It has also been discovered that the present composition affords an increased bioavailability of the fenofibrate as compared to conventional formulations.

Although the present inventors do not wish to be bound by any particular theories, one plausible mechanism of operation for the present invention is that upon cooling, the melted mixture of hot fenofibrate-polyglycolized glycerides maintains the fenofibrate in liquid form. When absorbed in the gastrointestinal tract of a patient, the gastrointestinal fluids are able to dissolve the fenofibrate due to the HLB value of the excipient mixture, whereby fenofibrate is readily absorbed.

Generally, the composition of the present invention contains from about 5% to 95% by weight of fenofibrate and from about 95% to 5% by weight of excipient including one or more polyglycolized glycerides. It is preferred, however, if the present composition contains from about 20% to 80% by weight of fenofibrate and from about 80% to 20% by weight of excipient. It is even more preferred, however, if the present composition contains from about 30% to 70% by weight of fenofibrate and from about 70% to 30% by weight of excipient.

In a particularly preferred composition, generally about 45% to 55% by weight of fenofibrate is used and about 55% to 45% by weight of excipient containing the one or more polyglycolyzed glycerides is used.

Generally, the method of the present invention entails adding one or more excipients, including the one or more polyglycolyzed glycerides to containing means and then heating the excipients until all components are melted. Then, fenofibrate is added slowly with continuous stirring until all fenofibrate added is dissolved. Stirring is then continued for about 10 minutes to about 1 hour, and preferably for about 15 minutes to about 30 minutes. Then, containing means for the pharmaceutical composition, such as hard gelatin capsules, are filled with the composition using a liquid filing capsule machine having dosing pumps which are heated to the same temperature as the temperature of the molten pharmaceutical composition. Generally, this temperature is about 55° C. to about 95° C. more typically in the range of about 80° C. to 90° C. Upon cooling to ambient temperature, the capsules are packed in bottles. When capsules of size 3 are used, each capsule so prepared contains 67 mg of fenofibrate.

It is advantageous, however, to use the following protocol. To about 3 parts by weight polyglycolized glyceride excipient having a melting point of 44° C. and an HLB value of 14 molten at 80° C., is added about 2 parts by weight of fenofibrate and about 1 part by weight of hydroxypropyl cellulose. After maintaining the solution under agitation for about 20 additional minutes, hard gelatin capsules are filled therewith.

The present invention will now be further described by reference to certain examples which are provided solely for purposes of illustration and are not intended to be limitative.

______________________________________Fenofibrate           6.7    kgGelucire ® 44/14  5.0    kgPolyoxamer 407        5.0    kg                 16.7   kg______________________________________

In a stainless steel container, were introduced 5 kg of Gelucire®44/14 and 5 kg of Poloxamer 407, which were then heated at 85° C. until all components are molten. 6.7 kg of fenofibrate was added slowly while continuously stirring the mixture. When all of the fenofibrate was dissolved agitation was maintained for about twenty minutes. Using a liquid filing capsule machine with dosing pumps heated at 85° C., capsules of size 3 was filled with 167 mg of solution. Upon cooling at room temperature the capsules were packaged in bottles. Each capsule so prepared contained 67 mg of fenofibrate.

PHARMACOKINETICAL STUDY

The composition of Example 1 was compared to conventional form in a pharmacokinetical study with 15 healthy subjects. Each subject received 3 capsules of composition of Example 1 (201 mg of fenofibrate) or 3 capsules of Lypantyl 100®(300 mg of the conventional form). The sessions were separated by a wash out period of 7 days. The medications were taken after a high-fat breakfast. Blood samples were obtained before and at different times up to 72 hours after administration. The plasma concentration of fenofibric acid was determined in all available samples using a conventional HPLC method.

  - Plasma Fenofibric Acid Concentration (mg.l vs. time (h) After Administration  at 3 Capsules of Example 1 (Total amount of Fenofibrate administered: 201 mg)  Post-dose  time (h) 1 2 3 4 5 6 8 9 10 11 12 13 14 15 16 Mean* SD  0 BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ 0 --  1 BLOQ BLOQ 0.42 BLOQ 0.52 0.81 0.29 BLOQ 0.32 BLOQ BLOQ BLOQ BLOQ 0.81 BLOQ 0.21 0.30  2 0.36 0.34 3.87 4.31 5.10 6.00 4.66 6.46 2.56 BLOQ 0.99 1.09 3.84 3.03 0 .75 2.89 2.19  3 3.31 1.06 7.52 8.12 12.80 7.68 7.50 7.27 6.55 2.51 3.83 3.22 12.68 6.73 5.62 6.43 3.37  4 4.06 2.70 6.02 10.87 13.56 8.27 0.42 8.93 8.16 4.46 5.35 5.23 13.93 7.17 9.61 7.85 3.33  5 4.06 5.49 6.61 10.84 12.65 6.99 9.64 11.70 9.65 6.49 7.42 5.46 14.41 8.53 11.08 8.73 2.99  6 4.32 7.17 6.42 10.68 12.34 6.32 12.19 16.75 11.64 9.75 12.16 5.76 15.68 9.95 13.70 10.32 3.71  7 3.82 7.60 4.28 8.50 11.75 5.68 8.93 8.45 11.43 8.89 11.41 3.74 7.60 9.06 10.72 8.12 2.71  9 4.74 6.83 3.71 5.28 9.61 4.27 8.12 6.19 9.97 6.80 8.79 3.57 7.41 6.42 8.70 6.76 2.05  12 5.61 8.07 2.36 5.66 8.08 3.49 7.05 4.70 7.78 5.00 7.00 6.25 3.75 4.83 6.49 5.74 1.73  24 2.57 3.56 0.85 2.48 4.78 1.39 2.51 1.83 3.48 2.19 2.32 2.30 3.67 2.29 2.64 2.59 0.97  36 1.24 1.53 0.61 1.64 3.01 0.63 1.73 1.16 2.38 1.42 1.64 1.24 1.74 1.26 1.26 1.50 0.61  48 0.80 0.76 0.27 0.98 2.13 0.29 1.05 0.95 1.54 1.06 1.10 0.63 1.33 0.73 0.88 0.97 0.47  60 0.55 0.70 BLOQ 0.64 1.43 0.28 0.73 0.43 0.88 0.73 0.92 0.28 0.78 0.48 0.70 0.64 0.33  72 0.40 0.52 BLOQ 0.50 1.21 BLOQ BLOQ 0.38 0.68 0.51 0.53 BLOQ 0.62 BLOQ 0.39 0.38 0.34  Plasma Fenofibric Acid Concentration (mg.l vs time (h) After Administrat ion  at 3 Capsules of the Conventional Form (Total amount of Fenofibrate administered: 300 mg)  Post-dose  time (h) 1 2 3 4 5 6 8 9 10 11 12 13 14 15 16  0 BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ  1 BLOQ BLOQ BLOQ 0.25 BLOQ BLOQ 1.90 BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ  2 BLOQ BLOQ 0.25 4.67 0.34 1.52 5.83 BLOQ BLOQ 0.42 0.63 BLOQ BLOQ BLOQ 1 .28  3 1.75 0.99 2.16 7.39 4.51 3.72 5.89 2.45 1.53 1.71 1.55 1.03 1.40 0.47 3.79  4 3.25 4.62 5.57 9.13 8.83 5.00 5.76 5.12 6.54 4.37 3.58 3.47 4.75 1.48 5.08  5 4.53 10.24 12.20 12.16 10.43 4.77 6.57 11.97 12.91 4.93 6.94 4.22 6.40 3.55 11.35  6 8.77 17.36 12.93 12.08 13.18 5.66 6.62 14.17 18.00 9.03 11.45 4.30 11.12 10.65 17.47  7 4.75 11.92 12.12 10.71 11.36 4.84 5.90 12.31 14.42 8.08 10.58 4.17 13.21 10.11 16.35  9 3.64 8.21 9.29 8.39 9.62 6.34 5.80 7.33 10.86 6.37 8.25 6.34 10.22 7.21 11.79  12 4.24 7.03 6.20 6.90 7.96 8.66 5.30 6.67 7.50 5.11 7.09 12.05 9.16 5.74 8.06  24 2.36 3.43 1.88 3.12 4.76 2.53 2.19 2.61 2.85 2.66 2.85 6.53 4.92 2.29 3.08  36 1.17 2.03 0.92 1.56 3.27 0.95 1.47 1.14 1.73 1.48 1.38 3.31 2.31 1.33 1.69  48 0.70 1.17 0.61 1.02 2.06 0.49 0.71 0.94 0.90 1.07 0.92 1.72 1.39 0.81 1.03  60 0.49 0.50 0.43 0.66 1.77 0.31 0.74 0.81 0.58 0.69 0.55 0.81 1.13 0.54 0.74  72 BLOQ BLOQ 0.30 0.49 1.48 BLOQ 0.49 0.54 0.34 0.52 0.40 BLOQ 0.83 0.35 0.40

The bioavailability, as measured by the extent of absorption (AUC) indicates, that 3 capsules of Example 1 of the present invention (201 mg of fenofibrate AUC=195) are bioequivalent to 3 capsules of the conventional form (300 mg of fenofibrate AUC=221).

That is, the bioavailability of fenofibrate from the composition of Example 1 of the present invention is 1.5 times higher than the bioavailability of fenofibrate of the conventional form.

______________________________________Fenofibrate            5      kgGelucire ® 44/14   7.5    kgCarbowax 20,000        1.5    kgHydroxypropylcellulose 2.5    kg                  16.5   kg______________________________________

To a heated kettel, 7.5 kg of Gelucire®44/14 and 1.5 kg of carbowax 20,000 were added and then heated at 85° C. until all components are molten. 5 kg of fenofibrate was added slowly while continuously stirring. When all the fenofibrate was dissolved, 2.5 kg of hydroxypropylcellulose was added and agitation was maintained for about twenty minutes. Using a liquid filing capsule machine with dosing pumps heated at 85° C., capsules of size 0 were filled with 660 mg of solution. Upon cooling at room temperature the capsules were packaged in bottles. Each capsule so prepared contained 200 mg of fenofibrate. 12,701 capsules were produced and individually weighed. Results of the capsule weighing is shown in Table 3.

              TABLE 3______________________________________Capsules Weight Variations From 12,701 Capsules______________________________________Theoretical Weight      764.5 mgMean weight of acceptable                   763.9 mgcapsules (95-105%)Standard Deviation of   6.9 mgAccepted CapsulesRelative Standard Deviation                   0.9%of Accepted CapsulesPercent of Rejected     0.307%Capsules (below 95% ofTheoretical Amount)Percent of Rejected     0.039%Capsules (above 105% ofTheoretical Amount)______________________________________

It may readily be appreciated from Table 3 that the filling process of the present invention is extremely accurate.

PHARMACOKINETICAL STUDY

The composition of Example 2 of the present invention was compared during a Pharmacokinetical study to the co-micronized formulation available on the French market (Lypanthyl 200 M®).

The study was conducted as a single dose, randomized, four-way cross over study in 8 healthy subjects. The subjects were randomly assigned to one of four administration sequences. On each of the four sessions, separated by wash-out periods of 7 days, the subjects received either 200 mg of fenofibrate under the form Lypantyl 200 M® or 200 mg of fenofibrate under the form of Example 2 with and without a high-fat breakfast. Blood samples were taken before and at different times up to 72 hours after administration. The plasma concentrations of fenofibric acid was determined in the samples using on HPLC Method.

The pharmacokinetics parameters obtained are shown in Table 4.

              TABLE 4______________________________________Pharmacokinetical Parameters AfterAdministration of Lypantyl 200 M ® and Composition ofExample 2 Taken With and Without a high Fat Breakfast(Dose 200 mg of Fenofibrate)Without Food        With Food         Lipanthyl            LypanthylExample 2     200 M ®                   Example 2  200 M ®______________________________________AUC0-72  107.0      101.0     181.0    184.7Cmax  5.1        5.9       11.1     10.9τmax  5.9        5.2       5.2      5.7______________________________________

The present composition may thus be advantageously used to treat hyperlipidemia and/or hypercholesterolemia in humans. Generally, the effective daily amount of fenofibrate from humans ranges from about 100 mg to 600 mg per day, and preferably from about 100 to 300 mg per day, with the precise amount being determined by the attending physician, considering such parameters as condition severity and body weight, for example.

Having fully described the present invention, it will be apparent to one of ordinary skill in the art that many changes and modification may be made to the above-described embodiments without departing from the spirit and scope of the present invention.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US4416877 *Oct 9, 1981Nov 22, 1983Symphar S.A.Anti-atherosclerotic pharmaceutical compositions containing diphosphonate compounds
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US6074670 *Jan 9, 1998Jun 13, 2000Laboratoires Fournier, S.A.Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US6277405May 18, 2000Aug 21, 2001Labaratoires Fournier, S.A.Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US6368620 *Jun 11, 1999Apr 9, 2002Abbott LaboratoriesAntilipemic agent
US6368622Jan 29, 1999Apr 9, 2002Abbott LaboratoriesProcess for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US6372251Jun 11, 1999Apr 16, 2002Abbott LaboratoriesBioavailability
US6444225 *Sep 16, 1998Sep 3, 2002Bernard Charles ShermanBioavailability;melting, solidification
US6524615 *Feb 21, 2001Feb 25, 2003Kos Pharmaceuticals, IncorporatedHard shell capsule and a formulation comprising water insoluble medicament, high melting fatty ester, low viscosity oil, cellulosic polymer, and nonionic surfactant
US6589552Apr 22, 2002Jul 8, 2003Laboratoires Fournier, S.A.Microstructure grains; fine particle size
US6596317Feb 21, 2002Jul 22, 2003Laboratoires Fournier, SaFenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US6652881Nov 6, 2002Nov 25, 2003Laboratories Fournier, S.A.Micronized, quick dissolving; water, polysorbate 80 and sodium lauryl sulfate
US6682761Apr 20, 2001Jan 27, 2004Rtp Pharma, Inc.Water-insoluble drug particle process
US6709675 *Jul 5, 1999Mar 23, 2004Pierre Fabre MedicamentPrevents leakage between capsule parts
US6719999Mar 31, 1999Apr 13, 2004Abbott LaboratoriesLipid-regulating agent dissolved in one or more non-aqueous and/ or water-miscible solvents
US6814977Dec 18, 1998Nov 9, 2004Abbott LaboratoriesFenofibrate, 2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-propanoic acid, 1-methylethylester, having enhanced bioavailability when compared to commercially available formulations
US6838091Dec 18, 1998Jan 4, 2005Abbott LaboratoriesLipid-regulating agent, particularly fenofibrate, dissolved in a monoglyceride.
US6982281Nov 17, 2000Jan 3, 2006Lipocine IncPharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US7014864Dec 18, 1998Mar 21, 2006Abbott Laboratoriescontains fenofibrate and caprylic/capric/lauric triglycerides; for treatment of hyperlipidemia
US7022337 *Jun 27, 2003Apr 4, 2006Shire Laboratories, Inc.Self-emulsifying formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability and/or reduced food effect
US7037529Jul 6, 2001May 2, 2006Laboratoires FournierSpraying a suspension of microionized fenofibrate and polyvinylpyrrolidone onto an inert hydrosoluble carrier; immediate-release; improved dissolution
US7041319Nov 8, 2002May 9, 2006Laboratoires FournierFenofibrate pharmaceutical composition having high bioavailabilty
US7101574 *Jul 7, 2000Sep 5, 2006Laboratoires Des Produits Ethiques EthypharmPharmaceutical composition containing fenofibrate and the preparation method
US7276249May 23, 2003Oct 2, 2007Elan Pharma International, Ltd.Phospholipid-free, having a D50 particle size of less than 500 nm, andhaving a surface stabilizer; improved pharmacokinetic profiles and reduced fed/fasted variability
US7320802Oct 27, 2003Jan 22, 2008Elan Pharma International, Ltd.Improved pharmacokinetic profiles; bioadhesives
US7357931Dec 1, 2004Apr 15, 2008Alcon, Inc.Gene expression inhibition; drug screening; peroxisome proliferator-activated receptor agonists such as fenofibrate
US7361482 *Oct 31, 2003Apr 22, 2008Trustees Of Dartmouth CollegeUsing labeled c theta complex in permeabilized cells to detect and monitor cholesterol accumulation; diagnosing neurodegenerative diseases; drug screening
US7364752Nov 10, 2000Apr 29, 2008Abbott LaboratoriesSolid dispersion pharamaceutical formulations
US7662389Dec 22, 2006Feb 16, 2010Alcon, Inc.Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
US7863331 *Oct 3, 2003Jan 4, 2011Ethypharmmicronized fenofibrate, a surfactant and a binding cellulose derivative as a solubilization adjuvant that improves bioavailability; reducing food effect when treating hyperlipemias; FDA Orange book listed patent for fenofibrate
US7927627May 23, 2007Apr 19, 2011Elan Pharma International, Ltd.Nanoparticulate fibrate formulations
US7931917May 23, 2007Apr 26, 2011Elan Pharma International, Ltd.Phospholipid-free, having a D50 particle size of less than 500 nm, and having a surface stabilizer; improved pharmacokinetic profiles and reduced fed/fasted variability
US8025899Aug 25, 2004Sep 27, 2011Abbott LaboratoriesSolid pharmaceutical dosage form
US8026281Apr 22, 2005Sep 27, 2011Lupin Atlantis Holdings, S.A.Treating metabolic syndrome with fenofibrate
US8268349Apr 18, 2012Sep 18, 2012Abbott LaboratoriesSolid pharmaceutical dosage form
US8309613Sep 13, 2010Nov 13, 2012Abbvie Inc.Solid pharmaceutical dosage form
US8329214Mar 21, 2007Dec 11, 2012Laboratoires Fournier S.A.Process for producing fenofibrate tablets
US8333990Sep 13, 2010Dec 18, 2012Abbott LaboratoriesSolid pharmaceutical dosage form
US8343540Mar 21, 2007Jan 1, 2013Laboratories Fournier S.A.Process for producing fenofibrate tablets
US8377952Feb 23, 2005Feb 19, 2013Abbott LaboratoriesSolid pharmaceutical dosage formulation
US8399015Sep 22, 2011Mar 19, 2013Abbvie Inc.Solid pharmaceutical dosage form
US8470347May 29, 2001Jun 25, 2013AbbVie Deutschland GmbH and Co KGMixture of active materials, lipid and binder
US8524280Dec 15, 2009Sep 3, 2013Banner Pharmacaps, Inc.Methods for enhancing the release and absorption of water insoluble active agents
US8529952Jan 13, 2010Sep 10, 2013Ethypharmimproved bioavailabilty; micronized fenofibrate, a surfactant and a binding cellulose derivative as a solubilization adjuvant
US8563042Jun 25, 2010Oct 22, 2013EthypharmPharmaceutical composition containing fenofibrate and method for the preparation thereof
US8658212Aug 25, 2006Feb 25, 2014EthypharmPharmaceutical composition containing fenofibrate and method for the preparation thereof
US8691878Nov 12, 2012Apr 8, 2014Abbvie Inc.Solid pharmaceutical dosage form
US8778922Aug 22, 2012Jul 15, 2014Lipocine Inc.Steroidal compositions
WO2003013608A1Aug 7, 2002Feb 20, 2003Galephar M FORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINAITION OF PPARα AND A HMG-COA REDUCTASE INHIBITOR
WO2004002414A2 *Jun 27, 2003Jan 8, 2004Shojaei H AmirSelf-emulsifying formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability and/or reduced food effect
WO2005060542A2 *Dec 1, 2004Jul 7, 2005Alcon IncUse of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
WO2010075065A2Dec 15, 2009Jul 1, 2010Banner Pharmacaps, Inc.Methods for enhancing the release and absorption of water insoluble active agents
WO2011000126A1 *Jun 29, 2009Jan 6, 2011Yu LiuPharmaceutical composition of liposoluble drugs, preparation method and use thereof
Classifications
U.S. Classification514/49, 424/463, D24/100, 424/1.73, 424/456, 424/490, 424/492, 424/478
International ClassificationA61K31/216, A61K47/14, A61P3/06, A61K9/48, A61K31/195
Cooperative ClassificationA61K9/4858, A61K31/216, A61K9/4866
European ClassificationA61K31/216, A61K9/48H4, A61K9/48H6
Legal Events
DateCodeEventDescription
Jul 22, 2008SULPSurcharge for late payment
Year of fee payment: 11
Jul 22, 2008FPAYFee payment
Year of fee payment: 12
Feb 18, 2008REMIMaintenance fee reminder mailed
Apr 19, 2004FPAYFee payment
Year of fee payment: 8
Apr 19, 2004SULPSurcharge for late payment
Year of fee payment: 7
Mar 4, 2004REMIMaintenance fee reminder mailed
Dec 30, 1999FPAYFee payment
Year of fee payment: 4
Apr 27, 1995ASAssignment
Owner name: GALEPHAR P.R. INC., PUERTO RICO
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DEBOECK, ARTHUR;MAES, PAUL;BAUDIER, PHILLIPE R.;REEL/FRAME:007450/0590;SIGNING DATES FROM 19950314 TO 19950317